Professor Shaked’s lab studies patients’ responses to common cancer treatments, with an eye towards understanding why tumors return and even metastasize after initial treatment success. He found that chemotherapy can contribute to cancer cell resistance or spread by provoking the body to protect its cancer cells from the toxic effects of the drugs. This research paves the way for new cancer treatments that block the body’s protective patterns and increase therapeutic outcome.
Most recently, Prof. Shaked and researchers at the RTICC, including Professor Irit Ben-Aharon, director of the Division of Oncology at Rambam Medical Center, investigated the widely held assumption that cancer patients are an at-risk group for COVID-19. Their findings suggest most cancer patients are not at a higher risk of becoming infected than the population at large, and might, in fact, have the same if not better odds of beating back the most severe symptoms of COVID-19.
In addition to his academic career, Prof. Shaked is an industry consultant and co-founder of three biotech companies, one of which is in an advanced clinical study of precision medicine in oncology.
Prof. Shaked earned his bachelor’s degree in medical science from the Hebrew University of Jerusalem in 1997, and his doctorate from the Department of Neurology at Hadassah University Hospital in 2002, studying the biochemical aspects of neurodegenerative disorders. He completed six years of postdoctoral training at the University of Toronto and joined the Technion in 2008 as a Landau Fellow in the Leaders in Science and Technology Program.
He holds several U.S. patents, and has received numerous scholarships, awards, and research grants including the Krill Prize for Excellence in Scientific Research.